News | May 31, 2021
Aurobindo Pharma Q4FY21 consolidated net profit at Rs. 801.58 Cr
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Subscribe To Our Newsletter & Stay Updated
